clinical trial · NCT07185776
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Fujian Shengdi Pharmaceutical Co., Ltd.·phase2·active not recruiting·n = 203
Lipoprotein DisorderHRS-5632 InjectionHRS-5632 Injection Placebo
brief summary
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
started
Oct 21, 2025
primary completion
Apr 1, 2027
completion
Oct 1, 2027
last updated
Mar 5, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-5632 Injection in Adult Patients at High Risk of Cardiovascular Events With Elevated Lipoprotein(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol